Peptides vs. amphetamines for ADHD: what TikTok gets wrong

What did @clay.cognitiv actually say?

The creator argues that Adderall is overused by office workers and college students who mistake the feeling of productivity for actual output. His core claim: stimulants increase "the perceived value of a task," meaning you feel accomplished without necessarily doing more. He adds that cardiovascular and mental health costs are real, and that unspecified alternatives, likely peptides given his hashtags, are "much more sustainable" and take people further long-term.

To be fair, he frames this as satire and explicitly says stimulants have their place. That matters. This is a nuanced take dressed in TikTok hyperbole, not a flat denial of ADHD medication's legitimacy. But nuance gets lost fast at 83,700 views, so the claims deserve scrutiny anyway.

Does the science back this up?

Partly, yes. The dopamine-motivation piece is real, and so is tolerance. But the framing oversimplifies how amphetamines work in people who actually have ADHD versus those using stimulants off-label.

Research does support the idea that subjective productivity and objective output can diverge. A 2012 study by Ilieva et al. in Experimental and Clinical Psychopharmacology found that healthy non-ADHD adults taking amphetamines reported greater confidence in their work but showed no significant improvement, and sometimes worse performance, on tasks requiring fluid intelligence. That is a real finding, and the creator is directionally correct about perceived value inflating self-assessment.

On tolerance: amphetamine tolerance is well-documented. Volkow et al. (2012, Neuron) outlined how chronic dopamine stimulation downregulates D2 receptor density, which does erode therapeutic benefit over time. "The returns will diminish" is not wrong for off-label users, though it is more complicated for people with ADHD, where long-term studies show sustained functional benefit for many patients (Biederman et al., 2012, Journal of Clinical Psychiatry).

What did they get wrong (or right)?

The biggest problem is the logical fallacy in the opening. Pointing at college students who take Adderall and asking how far they have gotten is not evidence that Adderall caused underperformance. Correlation, selection bias, dose variation, diagnosis status, all of it is ignored. That argument does not hold up.

The cardiovascular risk framing is legitimate but underspecified. The FDA label for amphetamine salts does list increased heart rate and blood pressure as risks, and a 2023 review by Sciberras et al. in The Lancet confirmed small but measurable cardiovascular effects, particularly at higher doses. Citing this without context, though, makes it sound more alarming than it is for healthy adults at therapeutic doses.

What he got right: off-label stimulant use in neurotypical people is a legitimately gray area in the evidence base. The confidence-output gap is real. And the general point that stimulants are not universally optimal tools is defensible. Where he lost the thread is implying peptides fill that gap. That claim is not supported by anything approaching the evidence base that exists for amphetamines, even amphetamines' complicated one.

What should you actually know?

If you have a formal ADHD diagnosis, the evidence for stimulants is considerably stronger than this video implies. Meta-analyses, including Cortese et al. (2018, The Lancet Psychiatry), found amphetamines among the most effective short-term treatments for ADHD across all age groups, with effect sizes that are hard to dismiss.

If you are a neurotypical person using Adderall to get through a deadline, the picture is murkier, and the creator's skepticism is more applicable. Ilieva's work and subsequent studies suggest the cognitive benefits for healthy adults are modest and possibly offset by overconfidence effects.

On peptides: there is no peer-reviewed clinical trial showing that any peptide, BPC-157, semax, selank, or others, outperforms amphetamines for attention or productivity outcomes in humans. Animal model data exists. Human data is sparse, uncontrolled, and nowhere near regulatory approval. Calling peptides "much more sustainable" and implying they take people further is an extraordinary claim with no extraordinary evidence behind it. That part of the video should be taken skeptically.

The bottom line

This creator makes some defensible points about stimulant overconfidence and off-label use risks. But the framing collapses when you look at the ADHD-specific evidence, and the implicit promotion of peptides as superior alternatives is not backed by clinical data. Useful skepticism, executed with a significant evidence gap on one side.